Today: 19 July 2026
P&G stock slips as earnings near; what PG investors watch on Thursday
21 January 2026
2 mins read

P&G stock slips as earnings near; what PG investors watch on Thursday

New York, Jan 21, 2026, 11:55 ET — Regular session

Procter & Gamble shares fell 0.7% on Wednesday as investors positioned ahead of the consumer-products maker’s quarterly results due Thursday. The stock was down $1.06 at $145.94 in late-morning trade, after swinging between $145.43 and $147.38.

The report matters because P&G is an early read on how much pricing power big household brands still have, and whether shoppers are pushing back. In a market that has started to flinch at policy headlines, traders have been quick to hide in “defensive” names — and just as quick to leave.

Stocks more broadly steadied on Wednesday after Tuesday’s sharp selloff, which followed President Donald Trump’s tariff threats tied to his renewed push to acquire Greenland, Reuters reported. “But we’re certainly concerned about reigniting a trade war,” Art Hogan, chief market strategist at B Riley Wealth, said. The S&P 500 ETF SPY rose 0.7% while the consumer staples ETF XLP fell 0.5%. Reuters

P&G is scheduled to host its fiscal second-quarter earnings conference call on Jan. 22 at 8:30 a.m. ET, according to its investor relations events calendar. The focus will be on volumes, pricing and any tweak to the full-year view.

The stock had climbed 1.7% on Tuesday to close at $147.00, even as the broader market fell hard, according to MarketWatch. P&G outperformed several consumer and personal care peers on the day and remains well below its 52-week high of $179.99.

Analysts tracked by Zacks see fiscal second-quarter revenue of about $22.23 billion, up 1.6% from a year earlier, and earnings of $1.87 per share, down 0.5%, according to a Zacks preview carried by Finviz. Those are small moves, which can still be a problem for a stock that trades like a steady compounder.

In its last quarterly update in October, P&G kept its fiscal 2026 outlook intact, including sales growth of 1% to 5% and “core” earnings per share — an adjusted profit figure the company uses — of $6.83 to $7.09. It also flagged an after-tax commodity cost headwind and higher costs from tariffs for the full year, and defined “organic sales” as growth excluding currency and acquisitions and divestitures. Procter & Gamble

Dividend watchers also have a near-term calendar item: P&G said its board declared a quarterly dividend of $1.0568 per share, payable on or after Feb. 17 to shareholders of record on Jan. 23, a filing showed.

P&G’s results tend to echo across the household and personal care aisle, where investors have been leaning on predictable cash flows when the macro backdrop turns messy. This time, the market wants the boring details — whether the company can protect margins without leaning too hard on price.

The risk is that management strikes a more cautious tone on demand, or signals heavier discounting to defend share. Currency swings and input-cost moves can also whipsaw guidance, even for a company built to be steady.

Next up is Thursday’s quarterly report and the 8:30 a.m. ET conference call on Jan. 22, where investors will look for any shift in the full-year outlook and what P&G says about pricing, promotions and tariff-related costs.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • Molina Healthcare: Market Sentiment Misses the Mark
    July 19, 2026, 6:19 AM EDT. The market's reading of Molina Healthcare's valuation appears mistaken, opening a window for investors. An independent finance expert, experienced in macroeconomic analysis, technical patterns, and momentum-driven trading, makes the case that shares are currently undervalued. The analyst's method prioritises capital protection and a favourable risk-reward profile, blending Growth At A Reasonable Price (GARP) with momentum strategies for a balanced investment framework. The article highlights Molina Healthcare's prospects with actionable, data-backed observations in a turbulent market, encouraging investors to reassess the cautious outlook now prevailing.
OpenAI CFO Sarah Friar lifts lid on $20B revenue run rate as 2026 shifts to “practical adoption”
Previous Story

OpenAI CFO Sarah Friar lifts lid on $20B revenue run rate as 2026 shifts to “practical adoption”

Bloom Energy stock price slips as big-holder filings land ahead of Feb. 5 earnings
Next Story

Bloom Energy stock price slips as big-holder filings land ahead of Feb. 5 earnings

Go toTop